Windtree therapeutics, inc. WINT.US Overview
WINT AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
WINT Current Performance
4.89%
Windtree therapeutics, inc.
-1.83%
Avg of Sector
-0.40%
S&P500
WINT Key Information
WINT Revenue by Segments
Browsing restrictions can be lifted for a fee.
WINT Net Income
Browsing restrictions can be lifted for a fee.
WINT Cash Flow
Browsing restrictions can be lifted for a fee.
WINT Profit Margin
Browsing restrictions can be lifted for a fee.
WINT PE Ratio River
Browsing restrictions can be lifted for a fee.
WINT Financial Forecast
Browsing restrictions can be lifted for a fee.
WINT Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
WINT Profile
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
Price of WINT
WINT FAQ
When is WINT's latest earnings report released?
The most recent financial report for Windtree therapeutics, inc. (WINT) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating WINT's short-term business performance and financial health. For the latest updates on WINT's earnings releases, visit this page regularly.
How much debt does WINT have?
As of the end of the reporting period, Windtree therapeutics, inc. (WINT) had total debt of 1.58M, with a debt ratio of 0.06. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does WINT have?
At the end of the period, Windtree therapeutics, inc. (WINT) held Total Cash and Cash Equivalents of 1.18M, accounting for 0.04 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is WINT's EPS continuing to grow?
According to the past four quarterly reports, Windtree therapeutics, inc. (WINT)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -4.63. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of WINT?
Windtree therapeutics, inc. (WINT)'s Free Cash Flow (FCF) for the period is -2.41M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 18.32% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.